指南与共识神经康复脊髓损伤康复骨科与运动康复

欧洲专家共识:难治性痉挛患者选择鞘内巴氯芬和/或A型肉毒毒素治疗的算法

European expert consensus on improving patient selection for the management of disabling spasticity with intrathecal baclofen and/or botulinum toxin type A.
指南 / 共识 · J Rehabil Med · 2022-01-03

欧洲顾问委员会通过文献回顾和在线调查(79名专家,17国,应答率57%)制定成人难治性痉挛患者选择鞘内巴氯芬(ITB)和/或A型肉毒毒素(BoNT A)治疗的算法。共识认为多节段或全身性难治性痉挛是ITB最佳候选,局灶/节段性痉挛是BoNT A理想候选,并明确了不同痉挛分布类型对ITB的共识支持率。

要点

  • 多节段或全身性难治性痉挛患者是ITB最佳候选(96.1%共识)。
  • 局灶/节段性痉挛患者是BoNT A理想候选(98.7%共识)。
  • 双下肢痉挛、下肢+躯干痉挛、上下肢痉挛等类型对ITB有高共识支持。

核心结论

  • 该算法可辅助成人难治性痉挛患者选择ITB和/或BoNT A治疗。

研究设计与样本

  • 欧洲顾问委员会由4名神经科医生和4名康复专家组成,进行ITB和BoNT A治疗难治性痉挛的文献回顾。
  • 在线调查发送给125名医生和13名非医生痉挛专家,共79名专家(17国)完成,应答率57%。
  • 共识定义为≥75%受访者同意或中立。

主要发现

  • 多节段或全身性难治性口服药物痉挛患者是ITB最佳候选(96.1%共识)。
  • 局灶/节段性难治性痉挛患者是BoNT A理想候选(98.7%共识)。
  • 双侧下肢痉挛仅影响下肢是ITB良好候选(97.4%共识)。
  • 双侧下肢和躯干痉挛(100%共识)或单侧下肢和躯干痉挛(90.9%共识)是ITB良好候选。
  • 单侧或双侧上下肢痉挛是ITB良好候选(96.1%共识)。

关键数值与推荐

  • ITB最佳候选:多节段或全身性难治性痉挛(96.1%共识)。
  • BoNT A理想候选:局灶/节段性痉挛(98.7%共识)。
  • ITB良好候选:双侧下肢痉挛仅影响下肢(97.4%共识)。
  • ITB良好候选:双侧下肢和躯干痉挛(100%共识)或单侧下肢和躯干痉挛(90.9%共识)。
  • ITB良好候选:单侧或双侧上下肢痉挛(96.1%共识)。

临床怎么用

  • 临床可根据痉挛分布模式(多节段/全身性 vs 局灶/节段性)初步选择ITB或BoNT A。
  • 对双下肢、下肢+躯干、上下肢痉挛等特定分布类型可考虑ITB治疗。

局限性

  • 共识基于专家意见和文献回顾,未报告患者结局数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To develop an algorithm for the selection of adults with disabling spasticity for treatment with intrathecal baclofen (ITB) and/or botulinum toxin type A (BoNT A). METHODS: A European Advisory Board of 4 neurologists and 4 rehabilitation specialists performed a literature review on ITB and BoNT A treatment for disabling spasticity. An online survey was sent to 125 physicians and 13 non-physician spasticity experts. Information on their current clinical practice and level of agreement on proposed selection criteria was used to inform algorithm design. Consensus was considered reached when ≥75% of respondents agreed or were neutral. RESULTS: A total of 79 experts from 17 countries completed the on-line survey (57%). Agreement was reached that patients with multi-segmental or generalized disabling spasticity refractory to oral drugs are the best candidates for ITB (96.1% consensus), while those with focal/segmental disabling spasticity are ideal candidates for BoNT A (98.7% consensus). In addition the following are good candidates for ITB (% consensus): bilateral disabling spasticity affecting lower limbs only (97.4%), bilateral (100%) or unilateral (90.9%) disabling spasticity affecting lower limbs and trunk, and unilateral or bilateral disabling spasticity affecting upper and lower extremities (96.1%). CONCLUSION: This algorithm will support the management of adult patients with disabling spasticity by aiding patient selection for ITB and/or BoNT A treatments.

来源:J Rehabil Med,查看原文。版权归原作者所有。

引用

  1. Biering-Soerensen B, Stevenson V, Bensmail D, et al. European expert consensus on improving patient selection for the management of disabling spasticity with intrathecal baclofen and/or botulinum toxin type A. J Rehabil Med. 2022. PMID: 34608495. doi:10.2340/16501977-2877

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。